Ascent Wealth Partners’s iShares Biotechnology ETF IBB Stock Holding History

Ascent Wealth Partners’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,906	Closed	-$232K	–	125
2018 Q3	$232K	Sell	1,906 -121	-6%	-$14.2K	0.07%	118
2018 Q2	$223K	Buy	2,027 +20	+1%	+$2.14K	0.08%	119
2018 Q1	$214K	Buy	+2,007	New	+$222K	0.08%	117
2014 Q2	–	Sell	-5,043	Closed	-$398K	–	108
2014 Q1	$398K	Buy	+5,043	New	+$420K	0.27%	74

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Natixis Paris, France $28B AUM 26.79% 1-Year Est. Return

Ascent Wealth Partners's IBB Position: Q4 2018 in Review

Ascent Wealth Partners sold out of iShares Biotechnology ETF (IBB) in Q4 2018, closing a stake of 1,906 shares — an estimated $232K sold.

Ascent Wealth Partners first reported a position in IBB in Q1 2014 and held it in 4 quarters. The position peaked at $398K in Q1 2014. 649 funds tracked by Wall St. Rank hold IBB as of Q4 2018.

Ascent Wealth Partners reported no remaining iShares Biotechnology ETF position as of Q4 2018 after selling out during the quarter.
Ascent Wealth Partners sold 1,906 iShares Biotechnology ETF shares in Q4 2018, an estimated $232K.
Ascent Wealth Partners first reported a position in iShares Biotechnology ETF in Q1 2014 and held it in 4 quarters.
Ascent Wealth Partners's iShares Biotechnology ETF position peaked at $398K in Q1 2014.
649 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2018.

Based on Ascent Wealth Partners's 13F filing for Q4 2018, filed 13 Feb 2019.